[REVIEW] GL Biochem — compounded tirzepatide quality report

One concrete data point for the thread. Red flags, in rough order of how much they should worry you: no verifiable address, no batch numbers, prices far under market, vendor-commissioned tests only, pressure toward irreversible payment, and shipping with no temperature control.

A narrower follow-up, since the general answer is now clear:

What actually distinguishes 503A from 503B, in terms of what each may make and from what starting material?

HPLC_Greg said:

Red flags, in rough order of how much they should worry you: no verifiable address, no batch numbers, prices far under market, vendor-commissioned…

Adding the part of the answer the thread has not reached. The pattern that distinguishes a bad batch from an exit is behaviour rather than product. A bad batch comes with communication, a reshipment offer and a batch number. An exit comes with slower replies, pressure toward less reversible payment methods, sudden discounting, and the same reassurance repeated without any new information. The product tells you less than the correspondence does.

Reporting back.

The bulks-list asymmetry was the piece I had missed entirely. It explains why one of my two pharmacies is still arguing it can supply and the other simply stopped.

SleepDoc_PDX said:

The pattern that distinguishes a bad batch from an exit is behaviour rather than product.

Agreed, and the enforcement dates were staggered by category — 503A first, 503B a few weeks later — because outsourcing facilities have manufactured inventory and clinic contracts to unwind while a 503A makes to order.

Worth separating that from vendor vetting, which this thread keeps folding into the same question. They behave differently and the advice does not transfer.